Clinical Trials Browser

Fallopian Tube Neoplasms × Cell- and Tissue-Based Therapy × Clear all

NCT03691376 2024-09-19

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Terminated

Fallopian Tube Neoplasms, Ovarian Neoplasms